Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tennessee Medicaid Gets US Approval For Closed Formulary As Part Of ‘Capped’ Spending Program

Executive Summary

Demonstration, which may not survive scrutiny from the Biden Administration, includes some protections, such as prohibiting Tennessee from excluding drugs described in the Medicare Part D protected classes policy.

You may also be interested in...



Closed Formularies In Medicaid: Biden Orders Review Of Trump-Era Demonstrations, Waivers

Tennessee Medicaid demonstration approved by the Trump Administration and involving capped federal spending will likely be in the cross hairs of the federal agency review and possible withdrawal ordered by President Biden. But it's unclear whether the new Administration will also object to the demonstration's closed formulary. 

Dueling Messages For Pharma From US Medicaid Formulary Plan

The innovator biopharma industry understandably concerned about a Trump Administration proposal to allow states to implement restrictive formularies while still collecting mandatory rebates. But the formulary protections in the Trump plan are an important message about the likely shape of any future changes to the US market.

No Closed Formularies In Medicaid Without Forgoing Rebates, CMS Tells Massachusetts

US agency decision is a relief to manufacturers worried that the Massachusetts plan would lead to reduced drug access and heavier rebate burdens. 

Topics

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel